Activation of thyroid hormone receptor‐β improved disease activity and metabolism independent of body weight in a mouse model of non‐alcoholic steatohepatitis and fibrosis

Aimo Kannt,Paulus Wohlfart,Andreas Nygaard Madsen,Sanne Skovgård Veidal,Michael Feigh,Dieter Schmoll

DOI: https://doi.org/10.1111/bph.15427

IF: 7.3

2021-04-06

British Journal of Pharmacology

Abstract:Background and PurposeActivation of hepatic thyroid hormone receptor ß (THR‐ß) is associated with systemic lipid lowering, increased bile acid synthesis and fat oxidation. In patients with non‐alcoholic steatohepatitis (NASH), treatment with THR‐ß agonists led to reduction in hepatic steatosis and circulating lipids, and resolution of NASH. We chose resmetirom (MGL‐3196), a liver‐directed, selective THR‐ß agonist, as a prototype to investigate the effects of THR‐ß agonism in mice with diet‐induced obesity (DIO) and biopsy‐confirmed advanced NASH with fibrosis. Experimental ApproachC57Bl/6J mice were fed a diet high in fat, fructose and cholesterol for 34 weeks, and only biopsy‐confirmed DIO‐NASH mice with fibrosis were included. Resmetirom was then administered at a daily dose of 3 mg/kg p.o. over a period of eight weeks. Systemic and hepatic metabolic parameters, histological NAFLD activity and fibrosis scores, and liver RNA expression profiles were determined to assess the effect of THR‐ß agonism. Key ResultsTreatment with resmetirom did not influence body weight but led to significant reduction (p<0.05) in liver weight (‐43 %), hepatic steatosis (‐53 %), plasma ALT activity (‐49 %), liver and plasma cholesterol (‐27 % and ‐60 %, respectively), and blood glucose (6.3 vs. 7.5 mmol/l). These metabolic effects translated into significant improvement in NAFLD activity score. Moreover, lower α‐smooth muscle actin content and down‐regulation of genes involved in fibrogenesis indicated a decrease in hepatic fibrosis. Conclusion and implicationsOur model robustly reflected clinical observations of body weight‐independent improvements in systemic and hepatic metabolism including anti‐steatotic activity.

pharmacology & pharmacy